BRISTOL-MYERS SQUIBB CO. news, videos and press releases
For more news please use our advanced search feature.
BRISTOL-MYERS SQUIBB CO. - More news...
BRISTOL-MYERS SQUIBB CO. - More news...
- Building a Better Future: Bristol Myers Squibb 2023 ESG Report
- Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
- Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
- How Is BMS Making Progress on Its Renewable Energy Goals?
- Biking the Globe for C2C4C
- Moments of Serendipity As Our Teams 'Light the Night'
- Cancer Care Milestone Reached in Lesotho
- Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
- Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
- Thinking about buying stock in Apple, Bristol-Myers Squibb, Cronos Group, Coca-Cola, or Walgreens Boots Alliance?
-
Bristol hospital introduces 'zero tolerance' policy on staff abuse
- CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
- The University of Bristol Selects Signant Health's TrialConsent® to Assess the Impact and Value of eConsent in an Oncology Trial
- Thinking about buying stock in Bristol-Myers Squibb, Canopy Growth Corp, Intel, Target, or Tilray?
- Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
- Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
- Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
- Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients
- Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have...
- Thinking about trading options or stock in Broadcom, Bank of America, Bristol-Myers Squibb, Netflix, or Roku?
- Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights
- Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers
- CEMATRIX Corporation Retains Bristol Capital for Investor Relations Services
- Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019
- Bristol‑Myers Squibb Announces Dividend
- Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
- Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
- More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research
